444 related articles for article (PubMed ID: 27203857)
61. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
Grant JL; Hawkins C; Brooks H; Palella FJ; Koppe SW; Abecassis MM; Stosor V
AIDS; 2016 Jan; 30(1):93-8. PubMed ID: 26731756
[TBL] [Abstract][Full Text] [Related]
62. Treatment of chronic hepatitis C viral infection with sofosbuvir and daclatasvir in kidney transplant recipients.
Huang H; Tang H; Deng H; Shen J; Zhou Q; Xie W; Wu J; Chen J
Transpl Infect Dis; 2019 Feb; 21(1):e13018. PubMed ID: 30369001
[TBL] [Abstract][Full Text] [Related]
63. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant.
Fabrizi F; Martin P; Messa P
Kidney Int; 2016 May; 89(5):988-994. PubMed ID: 27083277
[TBL] [Abstract][Full Text] [Related]
64. Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease.
Taneja S; Duseja A; De A; Mehta M; Ramachandran R; Kumar V; Kohli HS; Gupta KL; Dhiman RK; Chawla Y
Dig Dis Sci; 2018 May; 63(5):1334-1340. PubMed ID: 29484572
[TBL] [Abstract][Full Text] [Related]
65. Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease.
Herzer K; Welzel TM; Spengler U; Hinrichsen H; Klinker H; Berg T; Ferenci P; Peck-Radosavljevic M; Inderson A; Zhao Y; Jimenez-Exposito MJ; Zeuzem S
Transpl Int; 2017 Mar; 30(3):243-255. PubMed ID: 28012215
[TBL] [Abstract][Full Text] [Related]
66. Increased peripheral CD4
Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
[TBL] [Abstract][Full Text] [Related]
67. Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience.
Chevallier E; Büchler M; Caillard S; Bouvier N; Colosio C; Rivalan J; Sayegh J; Bertrand D; Le Meur Y; Thierry A; Garrouste C; Rerolle JP; Rostaing L; Gatault P
Transplant Proc; 2020 Dec; 52(10):3179-3185. PubMed ID: 32636068
[TBL] [Abstract][Full Text] [Related]
68. Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature.
Fabbri G; Mastrorosa I; Vergori A; Mazzotta V; Pinnetti C; Grisetti S; Zaccarelli M; Ammassari A; Antinori A
BMC Infect Dis; 2017 Mar; 17(1):182. PubMed ID: 28249574
[TBL] [Abstract][Full Text] [Related]
69. Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure.
Dumortier J; Bailly F; Pageaux GP; Vallet-Pichard A; Radenne S; Habersetzer F; Gagnieu MC; Grangé JD; Minello A; Guillaud O; Kamar N; Alric L; Leroy V
Nephrol Dial Transplant; 2017 Dec; 32(12):2065-2071. PubMed ID: 27760839
[TBL] [Abstract][Full Text] [Related]
70. Perioperative Ledipasvir-Sofosbuvir for HCV in Liver-Transplant Recipients.
Levitsky J; Verna EC; O'Leary JG; Bzowej NH; Moonka DK; Hyland RH; Arterburn S; Dvory-Sobol H; Brainard DM; McHutchison JG; Terrault NA
N Engl J Med; 2016 Nov; 375(21):2106-2108. PubMed ID: 27959735
[No Abstract] [Full Text] [Related]
71. Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients.
Maasoumy B; Buggisch P; Mauss S; Boeker KHW; Müller T; Günther R; Zimmermann T; Manns MP; Sarrazin C; Hüppe D; Wedemeyer H; Vermehren J
Liver Int; 2018 Nov; 38(11):1906-1910. PubMed ID: 30022590
[TBL] [Abstract][Full Text] [Related]
72. Sofosbuvir Monotherapy for Asymptomatic and Noncirrhotic Hepatitis C Infection in a Renal Retransplantation Recipient: A Case Report.
Deng G; Ma J; Shen S; Li Q; Peng L; Meng S; Zhou J; Wu J; Liu D
Transplant Proc; 2016 Nov; 48(9):3120-3122. PubMed ID: 27932161
[TBL] [Abstract][Full Text] [Related]
73. Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens.
Maasoumy B; Vermehren J; Welker MW; Bremer B; Perner D; Höner Zu Siederdissen C; Deterding K; Lehmann P; Cloherty G; Reinhardt B; Pawlotsky JM; Manns MP; Zeuzem S; Cornberg M; Wedemeyer H; Sarrazin C
J Hepatol; 2016 Sep; 65(3):473-82. PubMed ID: 27085252
[TBL] [Abstract][Full Text] [Related]
74. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.
Aqel BA; Pungpapong S; Leise M; Werner KT; Chervenak AE; Watt KD; Murphy JL; Ryland K; Keaveny AP; McLemore R; Vargas HE
Hepatology; 2015 Oct; 62(4):1004-12. PubMed ID: 26096332
[TBL] [Abstract][Full Text] [Related]
75. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
76. Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin.
Shiffman ML; James AM; Long AG; Alexander PC
Am J Gastroenterol; 2015 Aug; 110(8):1179-85. PubMed ID: 26215530
[TBL] [Abstract][Full Text] [Related]
77. A real-life study on the impact of direct-acting antivirals in the treatment of chronic hepatitis C in liver transplant recipients at two university centers in Northeastern Brazil.
Silva IPL; Batista AD; Lopes EP; Filgueira NA; Carvalho BT; Santos JC; Medeiros TB; Melo CRL; Lima MS; Lima K; Lacerda C; Lacerda HR
Rev Inst Med Trop Sao Paulo; 2021; 63():e6. PubMed ID: 33533809
[TBL] [Abstract][Full Text] [Related]
78. Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients.
Saab S; Greenberg A; Li E; Bau SN; Durazo F; El-Kabany M; Han S; Busuttil RW
Liver Int; 2015 Nov; 35(11):2442-7. PubMed ID: 25913321
[TBL] [Abstract][Full Text] [Related]
79. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.
Comarmond C; Garrido M; Pol S; Desbois AC; Costopoulos M; Le Garff-Tavernier M; Si Ahmed SN; Alric L; Fontaine H; Bellier B; Maciejewski A; Rosenzwajg M; Klatzmann D; Musset L; Poynard T; Cacoub P; Saadoun D
Gastroenterology; 2017 Jun; 152(8):2052-2062.e2. PubMed ID: 28274850
[TBL] [Abstract][Full Text] [Related]
80. Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens.
Younossi ZM; Stepanova M; Nader F; Henry L
J Am Geriatr Soc; 2016 Feb; 64(2):386-93. PubMed ID: 26825683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
